Autopsy report · NCT04421222

Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer

“Study was terminated early due to a lack of improved efficacy.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 years 5 months before it stopped.
• 71 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

ESSA Pharmaceuticals

Sponsor type

Industry

Conditions

Prostate Cancer

Interventions

EPI-7386 (QD); EPI-7386 (BID); Abiraterone acetate; Apalutamide

Participants

71

Sites

9

Countries

Canada, United States

Trials that died the same way

• A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  “The study was early terminated due to lack of efficacy.” (98% match in meaning)
• Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
  “The study was terminated due to lack of efficacy.” (94% match in meaning)
• Dasatinib in Polycythemia Vera
  “This study was terminated due to lack of efficacy.” (94% match in meaning)
• A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
  “This study was terminated due to a lack of efficacy.” (94% match in meaning)
• A Study of LY3405105 in Participants With Advanced Cancer
  “The study was terminated for lack of sufficient efficacy.” (93% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.